Adapthealth Corp

AHCO is in a Stage 2 advance with a clear higher high/higher low structure and rising EMAs confirming upward momentum. The active continuation pattern signals bullish medium-term bias, supported by low transition risk. However, price is currently extended above the 9 and 21 EMAs with overbought conditions, making immediate entry less favorable. Execution should be deferred, stalking for pullbacks into the rising EMA support zone near the recent breakout level.

• ↑Q1 2026 revenue $819.8M (+5.4% YoY), beat guidance by $22M
• ↑Over 10 million patients in capitated contracts driving $200M+ in recurring revenue
• ↓Q1 net loss widened to $16M amid elevated labor costs